Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06810167 · ClinicalTrials.gov registry record · Phase 3
Assessing Tenapanor as a Treatment of CF-related Constipation.
A Phase 3 study of Cystic Fibrosis and Constipation, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT06810167: Recruiting Phase 3 study of Cystic Fibrosis and Constipation, sponsored by Massachusetts General Hospital.
NCT06810167 is a Phase 3 study of Cystic Fibrosis and Constipation that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 25 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06810167, a Phase 3 study of Cystic Fibrosis and Constipation, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. They will also complete three questionnaires, the PAC-SYM, PAC-QoL, and IBS-SSS, and daily diaries to characterize GI symptom burden and spontaneous bowel movement (SBM) frequency.
Primary Outcome
There will be a statistically significant increase in spontaneous bowel movement frequency (SBM) in cystic fibrosis patients with CF-related constipation receiving tenapanor.
Conditions Studied
Interventions
- DRUG Tenapanor
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
What NCT06810167 shows while recruiting
NCT06810167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which Tenapanor is the first listed.
NCT06810167 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06810167 about?
NCT06810167 is a clinical study titled "Assessing Tenapanor as a Treatment of CF-related Constipation.". Tenapanor is the newest FDA-approved drug for IBS with constipation (IBS-C). This study seeks to understand tenapanor as a treatment for cystic fibrosis-related constipation (CFrC) in CF patients. Participants will ingest one 50 mg tablet of tenapanor, twice daily, for a 4-week treatment period. The...
What is the current status of trial NCT06810167?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 25 participants. The study started on 2025-06-01. Estimated completion is 2027-06-30.
What conditions does trial NCT06810167 study?
This clinical trial studies the following conditions: Cystic Fibrosis, Constipation.
What interventions are being tested in trial NCT06810167?
The interventions under investigation include: Tenapanor (DRUG).
Who is sponsoring clinical trial NCT06810167?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06810167 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06810167's enrollment target sits among peer trials
25 122nd of 169 higher than 48 of 169 other Cystic Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cystic Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
RECRUITING · Phase 3
-
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
COMPLETED · Phase 3
-
Study of Ataluren (PTC124™) in Cystic Fibrosis
COMPLETED · Phase 3
-
Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease
COMPLETED · Phase 3
-
OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI